Viela Bio ^{Priced, Nasdaq: VIE}

We are a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, which we collectively refer to as autoimmune diseases. Our approach seeks to redefine the treatment of autoimmune diseases by focusing on critical biological pathways shared across multiple indications. We believe that this approach, which targets the underlying molecular pathogenesis of the disease, allows us to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple indications for each of our product candidates. Our lead product candidate, inebilizumab, is a humanized monoclonal antibody, or mAb, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells. We are initially developing inebilizumab as a first-line monotherapy for neuromyelitis optica spectrum disorder, or NMOSD, a rare, devastating condition that attacks the optic nerve, spinal cord and brain stem, and often leads to irreversible blindness and paralysis. In January 2019, we announced positive topline data from our N-MOmentum pivotal trial, the largest trial ever completed in the disease, in a broad patient population. We received Breakthrough Therapy Designation for inebilizumab for the treatment of this disease from the FDA, in April 2019, and in August 2019, the FDA accepted for review our Biologics License Application, or BLA, for inebilizumab.